CA3086642A1 - Compositions and methods of treatment of ehlers-danlos syndromes - Google Patents
Compositions and methods of treatment of ehlers-danlos syndromes Download PDFInfo
- Publication number
- CA3086642A1 CA3086642A1 CA3086642A CA3086642A CA3086642A1 CA 3086642 A1 CA3086642 A1 CA 3086642A1 CA 3086642 A CA3086642 A CA 3086642A CA 3086642 A CA3086642 A CA 3086642A CA 3086642 A1 CA3086642 A1 CA 3086642A1
- Authority
- CA
- Canada
- Prior art keywords
- histamine
- eds
- symptoms
- treatment
- ehlers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title abstract description 35
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract description 95
- 229960001340 histamine Drugs 0.000 claims abstract description 45
- 102000008186 Collagen Human genes 0.000 claims abstract description 34
- 108010035532 Collagen Proteins 0.000 claims abstract description 34
- 229920001436 collagen Polymers 0.000 claims abstract description 34
- 208000024891 symptom Diseases 0.000 claims abstract description 33
- 241000712079 Measles morbillivirus Species 0.000 claims abstract description 28
- 208000002193 Pain Diseases 0.000 claims description 29
- 230000036407 pain Effects 0.000 claims description 26
- 208000034264 Hypermobile Ehlers-Danlos syndrome Diseases 0.000 claims description 25
- 208000034260 Classical Ehlers-Danlos syndrome Diseases 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 229960001660 histamine phosphate Drugs 0.000 claims description 3
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical group OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000006866 deterioration Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 23
- 241000283690 Bos taurus Species 0.000 description 13
- 206010020751 Hypersensitivity Diseases 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 208000026935 allergic disease Diseases 0.000 description 13
- 230000007815 allergy Effects 0.000 description 13
- 206010016256 fatigue Diseases 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 208000034656 Contusions Diseases 0.000 description 12
- 208000005137 Joint instability Diseases 0.000 description 9
- 206010023204 Joint dislocation Diseases 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 7
- 229940126587 biotherapeutics Drugs 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 244000309466 calf Species 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000032544 Cicatrix Diseases 0.000 description 5
- 208000007379 Muscle Hypotonia Diseases 0.000 description 5
- 208000034259 Vascular Ehlers-Danlos syndrome Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 229940124873 Influenza virus vaccine Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 208000029725 Metabolic bone disease Diseases 0.000 description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 description 3
- 206010043101 Talipes Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011228 clubfoot Diseases 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 206010039722 scoliosis Diseases 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000567030 Ampulloclitocybe clavipes Species 0.000 description 2
- 208000034319 Arthrochalasia Ehlers-Danlos syndrome Diseases 0.000 description 2
- 208000021301 Bethlem myopathy 2 Diseases 0.000 description 2
- 201000003642 Brittle cornea syndrome Diseases 0.000 description 2
- 208000037033 Cardiac-valvular Ehlers-Danlos syndrome Diseases 0.000 description 2
- 208000036396 Dermatosparaxis Ehlers-Danlos syndrome Diseases 0.000 description 2
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 206010023506 Kyphoscoliosis Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 229940124862 Measles virus vaccine Drugs 0.000 description 2
- 208000031507 Musculocontractural Ehlers-Danlos syndrome Diseases 0.000 description 2
- 208000037044 Myopathic Ehlers-Danlos syndrome Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 208000037288 Periodontal Ehlers-Danlos syndrome Diseases 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 208000021375 Spondylodysplastic Ehlers-Danlos syndrome Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 206010002895 aortic dissection Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960004931 histamine dihydrochloride Drugs 0.000 description 2
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 2
- 208000035723 hypermobility type Ehlers-Danlos syndrome Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008111 motor development Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 208000019253 Acrogeria Diseases 0.000 description 1
- 206010063847 Arachnodactyly Diseases 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 208000009248 Congenital Hip Dislocation Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010073767 Developmental hip dysplasia Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000002325 Funnel Chest Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020046 High arched palate Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023201 Joint contracture Diseases 0.000 description 1
- 208000004733 Knee Dislocation Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010026865 Mass Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028331 Muscle rupture Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- 206010034204 Pectus excavatum Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 208000036742 Scleral discolouration Diseases 0.000 description 1
- 208000008877 Shoulder Dislocation Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000024337 Talipes equinovarus Diseases 0.000 description 1
- 206010043248 Tendon rupture Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229940105606 oxycontin Drugs 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940011043 percocet Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 208000022473 spontaneous ecchymoses Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A method is provided for treatment of symptoms of Ehlers-Danlos Syndromes comprising administration of a composition comprising rubeola virus, histamine and collagen.
Description
COMPOSITIONS AND METHODS OF TREATMENT OF EHLERS¨DANLOS SYNDROMES
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62/608,687, filed December 21, 2017, the disclosure of which is incorporated herein by reference in its entirety.
BACKGROUND OF INVENTION
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62/608,687, filed December 21, 2017, the disclosure of which is incorporated herein by reference in its entirety.
BACKGROUND OF INVENTION
[0002] The present invention is directed to methods and compositions for treatment of Ehlers-Danlos Syndrome (EDS). EDS is a disease complex that includes more than a dozen genetic disorders that cause defective processing of collagen, and as a result, weakened connective tissues in the body. As a broad generalization, these disorders reduce the strength and increase the elasticity of connective tissues in the body's frame (particularly those holding joints together) and may create life threatening flaws or weaknesses in the structure and performance of organs such as kidneys, intestines and blood vessels. Symptoms may include loose joints, stretchy skin, and abnormal scar formation. These can be noticed at birth or in early childhood. Complications may include aortic dissection, joint dislocations, scoliosis, chronic pain, or early osteoarthritis.
[0003] EDS is due to a mutation in one of more than a dozen different genes and affects about 1 in 5,000 people globally. The prognosis depends on the specific type.
While some types result in a normal life expectancy, those that affect blood vessels generally result in a shorter life expectancy. There is no known cure for EDS and treatment is supportive in nature.
For example, physical therapy and bracing may help strengthen muscles and support joints.
While some types result in a normal life expectancy, those that affect blood vessels generally result in a shorter life expectancy. There is no known cure for EDS and treatment is supportive in nature.
For example, physical therapy and bracing may help strengthen muscles and support joints.
[0004] The specific gene affected determines the type of EDS. Some cases result from a new mutation occurring during early development while others are inherited in an autosomal dominant or recessive manner. There are currently thirteen (13) different classifications of EDS.
The two most common types are hypermobile EDS (hEDS) and classical EDS (cEDS).
The remaining types are very rare.
The two most common types are hypermobile EDS (hEDS) and classical EDS (cEDS).
The remaining types are very rare.
[0005] EDS is estimated to affect 1 in 5,000 people. Hypermobile EDS
currently known as hEDS, which includes but is not limited to what was previously designated Type 3 EDS, is the most common of the various syndromes, affecting from a third to half of the entire EDS
population (1 in 10,000 to 15,000). Type 1 and 2 ¨ Classical EDS affects approximately I in 20,000 to 50,000 people. It is caused by autosomal dominant mechanism and affects type-V
collagen; as well as typel collagen. Type I Classical EDS typically presents with severe skin involvement while type 2 presents with mild to moderate skin involvement.
Patients with the Classical Type EDS may experience the same symptoms as the Hypermobility Type (hEDS).
The main difference between the hEDS and Classical Types is the Classical has more skin involvement while hEDS has more joint involvement, though patients with Classical EDS can also have severe joint issues and may respond well to MCC. Other variants such as vascular EDS (vEDS), which can lead to aortic dissection, represent even smaller patient populations.
vEDS is the only variant with current treatments in development (celiprolol and irbesartin). The classical form of EDS was the subject of an earlier clinical study evaluating the efficacy of IGF--I, which improved tendon collagen synthesis rates. There remains a need for a drug for the treatment of hEDS.
currently known as hEDS, which includes but is not limited to what was previously designated Type 3 EDS, is the most common of the various syndromes, affecting from a third to half of the entire EDS
population (1 in 10,000 to 15,000). Type 1 and 2 ¨ Classical EDS affects approximately I in 20,000 to 50,000 people. It is caused by autosomal dominant mechanism and affects type-V
collagen; as well as typel collagen. Type I Classical EDS typically presents with severe skin involvement while type 2 presents with mild to moderate skin involvement.
Patients with the Classical Type EDS may experience the same symptoms as the Hypermobility Type (hEDS).
The main difference between the hEDS and Classical Types is the Classical has more skin involvement while hEDS has more joint involvement, though patients with Classical EDS can also have severe joint issues and may respond well to MCC. Other variants such as vascular EDS (vEDS), which can lead to aortic dissection, represent even smaller patient populations.
vEDS is the only variant with current treatments in development (celiprolol and irbesartin). The classical form of EDS was the subject of an earlier clinical study evaluating the efficacy of IGF--I, which improved tendon collagen synthesis rates. There remains a need for a drug for the treatment of hEDS.
[0006] Identification of the subtype of EDS helps identify the nature of pathologies and their causes. A diagnosis is important because, although EDS is not curable, many symptoms are treatable. Treatment is supportive in nature. In most cases pain is a principal patient complaint, typically accompanied by high fatigue due to muscles working overtime to keep the body together. Drugs are prescribed to treat the pain but do nothing for the underlying cause of disease. Non-pharmacologic treatment of EDS patients is limited to physical therapy to help muscles to work better with ligaments to support joints and keep them safe.
Hydrotherapy is particularly helpful for aerobic exercise. Finally, bracing and casting can be helpful to support joints. Unfortunately, progressive disease often leads to a wheelchair and permanent incapacitation.
Hydrotherapy is particularly helpful for aerobic exercise. Finally, bracing and casting can be helpful to support joints. Unfortunately, progressive disease often leads to a wheelchair and permanent incapacitation.
[0007] Hypermobile EDS (hEDS) which includes but is not limited to what was previously designated Type 3 EDS, is characterized primarily by joint hypermobility affecting both large and small joints, which may lead to recurrent joint dislocations and subluxations (partial dislocation). In general, people with this type have soft, smooth and velvety skin with easy bruising and chronic pain of the muscles and/or bones.[
[0008] Classical EDS (cEDS) is associated with extremely elastic (stretchy), smooth skin that is fragile and bruises easily; wide, atrophic scars (flat or depressed scars); and joint hypermobility. Molluscoid pseudotumors (calcified hematomas over pressure points such as the elbow) and spheroids (fat-containing cysts on forearms and shins) are also frequently seen.
Hypotonia and delayed motor development may occur.
Hypotonia and delayed motor development may occur.
[0009] Vascular EDS (vEDS) is characterized by thin, translucent skin that is extremely fragile and bruises easily. Arteries and certain organs such as the intestines and uterus are also fragile and prone to rupture. People with this type typically have short stature; thin scalp hair;
and characteristic facial features including large eyes, a thin nose, and lobeless ears. Joint hypermobility is present, but generally confined to the small joints (fingers, toes). Other common features include club foot; tendon and/or muscle rupture; acrogeria (premature aging of the skin of the hands and feet); early onset varicose veins; pneumothorax (collapse of a lung); recession of the gums; and a decreased amount of fat under the skin.
and characteristic facial features including large eyes, a thin nose, and lobeless ears. Joint hypermobility is present, but generally confined to the small joints (fingers, toes). Other common features include club foot; tendon and/or muscle rupture; acrogeria (premature aging of the skin of the hands and feet); early onset varicose veins; pneumothorax (collapse of a lung); recession of the gums; and a decreased amount of fat under the skin.
[0010] Kyphoscoliosis EDS (kEDS) is associated with severe hypotonia at birth, delayed motor development, progressive scoliosis (present from birth), and sclera!
fragility. Affected people may also have easy bruising; fragile arteries that are prone to rupture; unusually small corneas; and osteopenia (low bone density). Other common features include a "marfanoid habitus" which is characterized by long, slender fingers (arachnodactyly);
unusually long limbs;
and a sunken chest (pectus excavatum) or protruding chest (pectus carinatum).
fragility. Affected people may also have easy bruising; fragile arteries that are prone to rupture; unusually small corneas; and osteopenia (low bone density). Other common features include a "marfanoid habitus" which is characterized by long, slender fingers (arachnodactyly);
unusually long limbs;
and a sunken chest (pectus excavatum) or protruding chest (pectus carinatum).
[0011] Arthrochalasia EDS (aEDS) is characterized by severe joint hypermobility and congenital hip dislocation. Other common features include fragile, elastic skin with easy bruising; hypotonia; kyphoscoliosis (kyphosis and scoliosis); and mild osteopenia.
[0012] Dermatosparaxis EDS (dEDS) is associated with extremely fragile skin leading to severe bruising and scarring; saggy, redundant skin, especially on the face;
and hernias. Brittle Cornea Syndrome (BCS) characterized by thin cornea, early onset progressive keratoglobus;
and blue sclerae.
and hernias. Brittle Cornea Syndrome (BCS) characterized by thin cornea, early onset progressive keratoglobus;
and blue sclerae.
[0013] Classical-like EDS (cIEDS) is characterized by skin hyperextensibility with velvety skin texture and absence of atrophic scarring, generalized joint hypermobility (GJH) with or without recurrent dislocations (most often shoulder and ankle), and easily bruised skin or spontaneous ecchymoses (discolorations of the skin resulting from bleeding underneath).
[0014] Spondylodysplastic EDS (spEDS) is characterized by short stature (progressive in childhood), muscle hypotonia (ranging from severe congenital, to mild later-onset), and bowing of limbs.
[0015] Musculocontractural EDS (mcEDS) is characterized by congenital multiple contractures, characteristically adduction-flexion contractures and/or talipes equinovarus (clubfoot), characteristic craniofacial features, which are evident at birth or in early infancy, and skin features such as skin hyperextensibility, easy bruisability, skin fragility with atrophic scars, increased palmar wrinkling.
[0016] Myopathic EDS (mEDS) is characterized by congenital muscle hypotonia, and/or muscle atrophy, that improves with age, Proximal joint contractures (joints of the knee, hip and elbow); and hypermobility of distal joints (joints of the ankles, wrists, feet and hands).
[0017] Periodontal EDS (pEDS) is characterized by severe and intractable periodontitis of early onset (childhood or adolescence), lack of attached gingiva, pretibial plaques; and family history of a first-degree relative who meets clinical criteria.
[0018] Cardiac-valvular EDS (cvEDS) is characterized by severe progressive cardiac-valvular problems (aortic valve, mitral valve), skin problems (hyperextensibility, atrophic scars, thin skin, easy bruising) and joint hypermobility (generalized or restricted to small joints).
[0019] Hypermobile EDS (hEDS) (also known as Type III EDS) is the most common form of EDS but no genetic basis for its genesis has been identified. In general hEDS
is considered less severe than the other types of EDS but significant complications, particularly those of the musculoskeletal system, do occur. The skin is often soft and can be mildly hyperextendible.
Subluxations and dislocations which can be acutely painful are said to be common and can occur spontaneously or with minimal trauma. Degenerative joint disease, easy bruising and chronic pain are common with the syndrome.
is considered less severe than the other types of EDS but significant complications, particularly those of the musculoskeletal system, do occur. The skin is often soft and can be mildly hyperextendible.
Subluxations and dislocations which can be acutely painful are said to be common and can occur spontaneously or with minimal trauma. Degenerative joint disease, easy bruising and chronic pain are common with the syndrome.
[0020] Hypermobile, or loose, joints that are not held tightly together by normally functioning collagen undergo frequent subluxations, dislocations and pain. This can be a significant problem when hyperextensible joints move beyond their normal range. Early onset osteoarthritis is a common consequence of this joint hypermobility as well.
Many patients with hypermobile joints also report fatigue, likely caused by muscles working overtime to keep the body together. EDS also presents with skin disorders such as hyperextensibility and tissue fragility. These characteristics, which can be noticed in early childhood, help define and differentiate between the multiple subtypes of EDS that are used for classification purposes.
Many patients with hypermobile joints also report fatigue, likely caused by muscles working overtime to keep the body together. EDS also presents with skin disorders such as hyperextensibility and tissue fragility. These characteristics, which can be noticed in early childhood, help define and differentiate between the multiple subtypes of EDS that are used for classification purposes.
[0021] Taken together all the fragmented data on pain manifestations and its possible underlying mechanisms in EDS indicate a complex pathogenesis. The slow progression from episodic, low-moderate, and treatment-responsive pain at single joints to chronic, severe and disabling pain affecting the entire body is indicative of multiple contributing pathologies. Some patients are able to localize pain and experience a satisfactory life, while others feel defeated and live a very restricted existence. For these reasons there remain a need in the art for more effective treatments of EDS and the symptoms of EDS.
[0022] Histamine [4--(2-aminoethyl)--imidazole or .beta.-imidazolyl-ethylamine] is a chemical substance possessing pronounced biological activities. It is a powerful stimulant of gastric secretion and constrictor of smooth muscle. It is a vasodilator and large doses cause a relatively rapid fall in blood pressure. It is frequently noted to be liberated by epithelial cells upon traumatic injury or stimulation by antigenic substances. Its storage in and release from mast cells and basophil granules and its role in Type I hypersensitivity reactions have been the subject of extensive study.
[0023] Of interest to the present application are the disclosures of US
5,877,198 which is directed to the administration of histamine for the treatment of the symptoms of urinary incontinence and US 6,156,780 which is directed to the administration of histamine for the treatment of the symptoms of fecal incontinence. Also of interest is the disclosure of published application US 2014/0121256 which is directed to the administration of histamine for the treatment of muscle weakness.
5,877,198 which is directed to the administration of histamine for the treatment of the symptoms of urinary incontinence and US 6,156,780 which is directed to the administration of histamine for the treatment of the symptoms of fecal incontinence. Also of interest is the disclosure of published application US 2014/0121256 which is directed to the administration of histamine for the treatment of muscle weakness.
[0024] Of further interest to the present application is the disclosures of US 4,521,405 which is directed to the administration of histamine and inactivated attenuated measles virus (rubeola) for the treatment of symptoms of Multiple Sclerosis and of US 4,705,685 which is directed to the administration of histamine and inactivated attenuated measles virus (rubeola) for the treatment of chronic pain.
[0025] Also of interest to the present invention is the disclosure of US
4,704,273 which is directed to a administering to a subject suffering from rheumatoid arthritis an effective amount of a composition comprising a mixture of histamine, immunoglobulin G provocative of rheumatoid factor formation or an immunologically active fraction thereof, collagen and attenuated measles virus (rubeola) for alleviating the symptoms of rheumatoid arthritis such as decreasing pain, increasing mobility and flexibility, decreasing swelling, decreasing inflammation and increasing energy. Other compositions comprising attenuated measles virus (rubeola) and histamine were reported to be useful in alleviating symptoms of rheumatoid arthritis while compositions comprising histamine alone or histamine in combination with immunoglobulin G
provocative of rheumatoid factor formation were reported to not be useful in alleviating such symptoms.
4,704,273 which is directed to a administering to a subject suffering from rheumatoid arthritis an effective amount of a composition comprising a mixture of histamine, immunoglobulin G provocative of rheumatoid factor formation or an immunologically active fraction thereof, collagen and attenuated measles virus (rubeola) for alleviating the symptoms of rheumatoid arthritis such as decreasing pain, increasing mobility and flexibility, decreasing swelling, decreasing inflammation and increasing energy. Other compositions comprising attenuated measles virus (rubeola) and histamine were reported to be useful in alleviating symptoms of rheumatoid arthritis while compositions comprising histamine alone or histamine in combination with immunoglobulin G
provocative of rheumatoid factor formation were reported to not be useful in alleviating such symptoms.
[0026] The patent further discloses administration of compositions comprising histamine, measles virus (rubeola) vaccine and influenza virus vaccine; of histamine and measles virus vaccine; and of histamine and influenza virus vaccine. The patent reported that subjects receiving the combination of histamine and measles virus vaccine with and without influenza virus vaccine had improvement of symptoms which those treated with the combination of histamine and influenza virus vaccine did not. Subjects treated with collagen and immunoglobulin G provocative of rheumatoid factor formation without rubeola virus or histamine did not report improvement in symptoms.
BRIEF SUMMARY OF THE INVENTION
BRIEF SUMMARY OF THE INVENTION
[0027] The present invention is directed to treatment of symptoms of Ehlers-Danlos Syndrome. In particular the invention is directed to treatment of one or more symptoms of Ehlers-Danlos Syndrome by the administration of a composition comprising rubeola virus, histamine and collagen and further optionally comprising immunoglobulin, including but not limited to IgG.
[0028] The invention is particularly directed to treatment of symptoms of hypermobile EDS
(hEDS) and classical EDS (cEDS) and treatment of symptoms of EDS where the symptoms are selected from the group consisting of pain (including maladaptive pain without tissue damage) fatigue, range of motion, emesis, and general quality of life as measured by tools such as the Short Form Health Survey (SF36) for measuring quality of life (QOL) and other similar assessments.
(hEDS) and classical EDS (cEDS) and treatment of symptoms of EDS where the symptoms are selected from the group consisting of pain (including maladaptive pain without tissue damage) fatigue, range of motion, emesis, and general quality of life as measured by tools such as the Short Form Health Survey (SF36) for measuring quality of life (QOL) and other similar assessments.
[0029] The compositions of the invention comprise rubeola (measles) virus in a dosage of from 0.4 ICI D50 to 400 ICI D50, more preferably 1 ICI D50 to 10 ICI D50 and most preferably 4 TCID50. Rubeola virus is commercially available in vaccine form such as attenuated live virus such as Attenuvax (Merck & Co., Whitehouse Station, NJ) but those of skill in the art would appreciate that other forms of rubeola virus including non-attenuated virus from other sources could be used in practice of the invention.
[0030] The composition further comprises histamine in a dosage of from 0.001 mg to 0.1 mg, more preferably 0.01 mg to 0.05 mg and most preferably 0.008 mg. Various forms of histamine can be used in the practice of the invention such as water soluble histamine salts including histamine phosphate. Those of skill in the art would appreciate other forms of histamine including histamine dihydrochloride would be useful in practice of the invention.
[0031] Collagen is present in the compositions of the invention in dosages of from 0.0001 mg to 0.1 mg, more preferably 0.001 mg to 0.01 mg and most preferably 0.002 mg. It is contemplated that any form of collagen from any source will be useful in practice of the invention and that the collagen may be denatured or non-denatured.
Particularly preferred is bovine calf collagen such as is available from Sigma-Aldrich (also known as Millipore-Sigma).
Particularly preferred is bovine calf collagen such as is available from Sigma-Aldrich (also known as Millipore-Sigma).
[0032] According to one aspect of the invention immunoglobulin can be incorporated into the compositions comprising Rubeola virus, histamine and collagen. Such compositions can comprise lmmunoglobulin in dosages of from 0.0001 mg to 0.3 mg, more preferably 0.001 mg to 0.03 mg and most preferably 0.003 mg. According to one aspect of the invention the lmmunoglobulin is human serum derived immunoglobulin but the source and immunological specificity of the lmmunoglobulin is not thought to be relevant to its utility in the practice of the invention.
[0033] A particularly preferred composition according to the invention comprises Rubeola virus at a dosage of 4 ICI D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg calf or bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
[0034] The compositions of the invention can be combined with pharmaceutically acceptable diluents, adjuvants and carriers as would be known to the art. The compositions can also be administered to the subjects to be treated parenterally or enterally.
According to one aspect of the invention the compositions can be administered parenterally to the subjects to be treated such as by subcutaneous injection but other sublingual administration is particularly preferred.
DETAILED DESCRIPTION OF THE INVENTION
According to one aspect of the invention the compositions can be administered parenterally to the subjects to be treated such as by subcutaneous injection but other sublingual administration is particularly preferred.
DETAILED DESCRIPTION OF THE INVENTION
[0035] The present invention is directed to treatment of symptoms of Ehlers-Danlos Syndrome. In particular the invention is directed to treatment of symptoms of one or more symptoms of Ehlers-Danlos Syndrome by the administration of compositions comprising an effective amount of a composition comprising rubeola virus, histamine and collagen,
[0036] According to one aspect of the invention a composition is provided which comprises a composition comprising rubeola virus, histamine and collagen. The components can be solubilized in phenylated saline and formulated to be administered by drop (0.05 mL) sublingually at various intervals daily to treat symptoms of EDS and particularly hEDS.
Nevertheless, given the heterogeneous causes of the many syndromes that fall under the Ehlers-Danlos label it is anticipated that many patients suffering from other types of EDS will respond to treatment with the compositions of the invention.
Nevertheless, given the heterogeneous causes of the many syndromes that fall under the Ehlers-Danlos label it is anticipated that many patients suffering from other types of EDS will respond to treatment with the compositions of the invention.
[0037] According to one aspect of the invention EDS symptoms of pain, fatigue, emesis can be reduced and joint mobility (range of motion) and quality of life measures can be improved by administration of the compositions of the invention.
[0038] The compositions of the invention comprise rubeola (measles) virus in a dosage of from 0.4 ICI D50 to 400 ICI D50, more preferably 1 ICI D50 to 10 ICI D50 and most preferably 4 TCID50. Rubeola virus is commercially available in vaccine form such as attenuated live virus such as Attenuvax (Merck & Co., Whitehouse Station, NJ) but those of skill in the art would appreciate that other forms of rubeola virus from other sources could be used in practice of the invention.
[0039] The composition further comprises histamine in a dosage of from 0.001 mg to 0.1 mg, more preferably 0.01 mg to 0.05 mg and most preferably 0.008 mg. Various forms of histamine can be used in the practice of the invention such as water soluble histamine salts including histamine dihydrochloride and histamine phosphate. One particularly useful source of histamine is Hollister-Stier Allergy (Spokane WA) Those of skill in the art would appreciate that other forms of histamine would be useful in practice of the invention.
[0040] Collagen is present in the compositions of the invention in dosages of from 0.0001 mg to 0.1 mg, more preferably 0.001 mg to 0.01 mg and most preferably 0.002 mg. Useful collagen can be denatured or undenatured and of any type derived from any animal source but a particularly preferred collagen is calf or bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma).
[0041] According to one aspect of the invention immunoglobulin can be incorporated into the compositions comprising Rubeola virus, histamine and collagen. Such compositions can comprise lmmunoglobulin in dosages of from 0.0001 mg to 0.3 mg, more preferably 0.001 mg to 0.03 mg and most preferably 0.003 mg. According to one aspect of the invention the immunoglobulin is human immune globulin such as is commercially available as GamaSTANTm (Talecris Biotherapeutics, Inc. Research Triangle Park, NC) which is believed to be primarily IgG but the immunological specificity of the lmmunoglobulin is not thought to be relevant to its utility in the practice of the invention.
[0042] A particularly preferred composition according to the invention comprises Rubeola virus at a dosage of 4 ICI D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), 0.002 mg calf or bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) and 0.003 mg lmmunoglobulin (GamaSTANTm Talecris Biotherapeutics, Inc. Research Triangle Park, NC) in a phenylated saline buffer.
[0043] It is preferred that initial treatment will involve four doses per day but patients can titrate their therapy to fewer doses after experiencing a therapeutic effect.
[0044] The compositions of the invention can be combined with pharmaceutically acceptable diluents, adjuvants and carriers as would be known to the art. It is contemplated that other suitable components could be combined with the components of the invention but none are required. The compositions can also be administered to the subjects to be treated parenterally or enterally. According to one aspect of the invention the compositions can be administered parenterally to the subjects to be treated such as by subcutaneous injection but other sublingual administration is particularly preferred.
[0045] According to this example, a woman diagnosed with hEDS was treated by sublingual administration four times daily with one drop (0.05 ml) of a composition comprising Rubeola virus at a dosage of 4 ICI D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) and 0.003 mg lmmunoglobulin (GamaSTANTm Talecris Biotherapeutics, Inc. Research Triangle Park, NC) in a phenylated saline buffer.
[0046] When the subject was evaluated after ten (10) days of treatment her physician reported the following:
[0047] "After only 10 days, she has had a remarkable alteration of her symptomology. Previously, she was a stay-at-home mother with a fulltime nanny, unable to care for her 3 children, couch-bound & only able to leave the house for perhaps an hour per day, only shop lx/week after which she would be unfunctional due to fatigue &
brain fog. She was consuming both LongActing Oxycontin and Oxycodone/Tylenol @ 6/day."
brain fog. She was consuming both LongActing Oxycontin and Oxycodone/Tylenol @ 6/day."
[0048] "Currently she has 'more energy than in past 10 years', is 'chasing the kids' around the house, was out of the house for 6 hours yesterday with no collapse afterwards. Her pain has diminished to point of reducing her pain meds from 6 Percocet/day to 2/d within a week, without any withdrawal symptoms. (She has been at this level of daily narcotics for 2 years)."
[0049] According to this example, a different female subject diagnosed with Type 3 Ehlers-Danlos Syndrome who had been suffering from the syndrome for about eight (8) years was treated by sublingual administration four times daily of one drop (0.05 ml) of a composition comprising Rubeola virus at a dosage of 4 ICI D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) and 0.003 mg lmmunoglobulin (GamaSTANTm Talecris Biotherapeutics, Inc. Research Triangle Park, NC) in a phenylated saline buffer.
[0050] When the subject was evaluated after approximately 60 days of days of treatment the treating physician reported the following:
[0051] "Patient reported that she had decreased her pain medication from where it was when we started. Her Fentanyl patch has decreased from 125 to 37 mg and the Gabapentin has decreased from 1200 to 300 to 600 at night. Her energy level was evidenced to be increased as the patient spontaneously lifted herself out of her wheelchair into a chair in our office. This observation of increased energy was reinforced by a report from her mother indicating that she was doing more for herself at home. Patient still reported spontaneously dislocating, and her sleep intervals have not apparently increased. Her personality was improved since last visit and she was more civil in her responses and her interactions."
[0052] According to this example, a middle aged male subject diagnosed with Type 3 Ehlers-Danlos Syndrome who had been suffering from the syndrome was treated by was treated by sublingual administration of one drop (0.05 ml) of a composition comprising Rubeola virus at a dosage of 4 ICI D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) and 0.003 mg lmmunoglobulin (GamaSTANTm Talecris Biotherapeutics, Inc. Research Triangle Park, NC) in a phenylated saline buffer. The subject reported reduced pain, reduced fatigue and improved quality of life.
[0053] According to this example a 61 year old female with joint hypermobility since childhood was treated She has not been classified as to EDS type by genetic evaluation, but would be classified as suffering from hEDS in the present vernacular. She is the owner of a small deli store where she works six days per week. At the time of initiating therapy she complained of soreness, tiredness, joint aches and pains, and difficulty making it through her long work days.
[0054] The subject was treated by sublingual administration four times daily of one drop (0.05 ml) of a three component composition comprising 4 ICI D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, and WA), 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
[0055] After six weeks of treatment with the three component composition the subject was treated by sublingual administration four times daily of one drop (0.05 ml) of administration of a four component composition comprising Rubeola virus at a dosage of 4 TCI D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), 0.002 mg calf or bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) and 0.003 mg lmmunoglobulin (GamaSTANTm Talecris Biotherapeutics, Inc.
Research Triangle Park, NC) in a phenylated saline buffer..
Research Triangle Park, NC) in a phenylated saline buffer..
[0056] The subject noted that while all the previous symptoms were still present were significantly reduced. Although she did not mention much about the state of loose joints at the first visit, at the six week mark she did say her shoulders felt better, or tighter. The subject reported reduced fatigue during the day after 10-14 days of treatment and reported that reduced pain was evident before the two week mark. No adverse effects were reported.
[0057] A 27 year old male diagnosed with hEDS (Type 3 EDS) suffered from weakness, pain, and joint dislocations and had difficulty sleeping and reported suffering from "brain fog."
The subject also reported that the symptoms of his condition made it difficult for him to maintain employment.
The subject also reported that the symptoms of his condition made it difficult for him to maintain employment.
[0058] The subject was treated by sublingual administration four times daily of one drop (0.05 ml) of a three component composition comprising Rubeola virus at a dosage of 4 TCID50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
[0059] After six weeks of treatment the subject reported that he felt stronger, had considerably less joint pain, had better sleeping patterns and reduced "brain fog." He especially noted that he could rotate his arm at the shoulder for the first time in months without pain and with an increase in range of motion without dislocation. No adverse effects were reported.
[0060] After six weeks of treatment with the three component composition the subject was treated by sublingual administration four times daily of one drop (0.05 ml) of administration of a four component composition comprising dosage of 4 TCI D50 (Attenuvax , Merck &
Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) and 0.003 mg lmmunoglobulin (GamaSTANTm Talecris Biotherapeutics, Inc. Research Triangle Park, NC) in a phenylated saline buffer. Administration of the four component mixture further comprising lmmunoglobulin maintained the improved symptoms but did not significantly improve them compared to when they were treated with the three component mixture.
Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) and 0.003 mg lmmunoglobulin (GamaSTANTm Talecris Biotherapeutics, Inc. Research Triangle Park, NC) in a phenylated saline buffer. Administration of the four component mixture further comprising lmmunoglobulin maintained the improved symptoms but did not significantly improve them compared to when they were treated with the three component mixture.
[0061] Ten additional patients suffering from forms of EDS have been treated by administration of the compositions of the invention and those subjects have reported improvements in symptoms similar to those reported above.
[0062] According to this example, a 21 year old female subject presented with a high arched palate, joint hypermobility, joint pain/dislocations, abnormal skin with easy bruising, abnormal scars, delayed wound healing, skin stretching and striae and myopia was diagnosed with hEDS
and had a Brighton score of 6/9. She also had soft/velvety skin, easy bruising, symptoms of Postural orthostatic tachycardia syndrome (POTS), and muscle pain.
and had a Brighton score of 6/9. She also had soft/velvety skin, easy bruising, symptoms of Postural orthostatic tachycardia syndrome (POTS), and muscle pain.
[0063] She was treated by sublingual administration four times daily of one drop (0.05 ml) of a three component composition comprising Rubeola virus at a dosage of 4 TCI
D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
[0064] The results of treatment presented in Table 1 below show improved generalized pain and improvements in the knee function. There were no changes in hypermobility, soft/velvety skin, or easy bruising but she was able to exercise for longer periods without pain and was eating a healthier diet. On one case, where she missed her dosage she passed out as a result of POTS.
SF-36 scores: initiation of therapy and most current (0=poor; 100=optimal) Day 1 Day 471 Difference physical functioning 40 80 40 role limitations due physical health 0 50 50 role limitations due emotional problems 33.3 0 -33.3 energy/fatigue 15 15 0 emotional well-being 36 12 -24 social functioning 37.5 25 -12.5 pain 12.5 57.5 45 general health 10 55 45
SF-36 scores: initiation of therapy and most current (0=poor; 100=optimal) Day 1 Day 471 Difference physical functioning 40 80 40 role limitations due physical health 0 50 50 role limitations due emotional problems 33.3 0 -33.3 energy/fatigue 15 15 0 emotional well-being 36 12 -24 social functioning 37.5 25 -12.5 pain 12.5 57.5 45 general health 10 55 45
[0065] According to this example, a 17 year old female subject presented with Initial symptoms of knee and shoulder dislocations, chronic fatigue and illnesses (e.g. mononucleosis, strep throat), easy scarring and bruising, swollen glands, and memory fog. She also had a 8/9 Brighton score and a physical exam revealed chronic fatigue, general pain, purplish, velvety skin highly reactive to hot/cold. The subject also presented as being uncomfortable, and having emotional difficulties including crying, panic attacks, and depression, shaking hands, pain and tingling throughout body, joint dislocations, irritable bowel syndrome, acid reflux, nausea, fatigue, dizziness, difficulty swallowing, rashes, dry-eye syndrome and mouth ulcerations.
[0066] She was treated by sublingual administration four times daily of one drop (0.05 ml) of a three component composition comprising Rubeola virus at a dosage of 4 TCI
D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
D50 (Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
[0067] After two weeks of treatment the patent reported improvement in all areas saying she had more energy and reported feeling as though she has normal health and has participated in more aspects of normal living including work, socializing and exercise. The results of treatment are presented in Table 2 below.
SF-36 scores: initiation of therapy and most current (0=poor; 100=optimal) Day 1 Day 241 Difference physical functioning 50 75 25 role limitations due physical health 50 50 0 role limitations due emotional problems 67 100 33 energy/fatigue 15 40 25 emotional well-being 60 64 4 social functioning 50 62.5 12.5 pain 45 55 10 general health 20 35 15 [0066] According to this example, subjects diagnosed with hEDS, cEDS and other EDS
variants are divided into control and treatment groups with the treatment groups treated according to a protocol in which they were treated by sublingual administration four times daily of one drop (0.05 ml) of a three component composition comprising Rubeola virus at a dosage of 4 TCID50(Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg calf or bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
[0069] The control and test subjects are evaluated prior to treatment for pain, fatigue, range of motion, emesis, and general quality of life such as can be measured by tools such as the Short Form Health Survey (SF36) and then periodically over a 90 day trial period and at the end of the trial period to determine the degree to which each symptom is improved.
[0070] Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the presently preferred embodiments thereof. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.
SF-36 scores: initiation of therapy and most current (0=poor; 100=optimal) Day 1 Day 241 Difference physical functioning 50 75 25 role limitations due physical health 50 50 0 role limitations due emotional problems 67 100 33 energy/fatigue 15 40 25 emotional well-being 60 64 4 social functioning 50 62.5 12.5 pain 45 55 10 general health 20 35 15 [0066] According to this example, subjects diagnosed with hEDS, cEDS and other EDS
variants are divided into control and treatment groups with the treatment groups treated according to a protocol in which they were treated by sublingual administration four times daily of one drop (0.05 ml) of a three component composition comprising Rubeola virus at a dosage of 4 TCID50(Attenuvax , Merck & Co., Whitehouse Station, NJ), 0.008 mg histamine (Hollister Stier Allergy, Spokane, WA), and 0.002 mg calf or bovine derived collagen from Sigma-Aldrich (also known as Millipore-Sigma) in a phenylated saline buffer.
[0069] The control and test subjects are evaluated prior to treatment for pain, fatigue, range of motion, emesis, and general quality of life such as can be measured by tools such as the Short Form Health Survey (SF36) and then periodically over a 90 day trial period and at the end of the trial period to determine the degree to which each symptom is improved.
[0070] Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the presently preferred embodiments thereof. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.
Claims (13)
1. A method of treating symptoms of an Ehlers-Danlos Syndrome in a subject suffering therefrom comprising the step of administering to said subject an effective amount of a composition comprising rubeola virus, histamine and collagen.
2. The method of claim 1 wherein the Ehlers-Danlos Syndrome is selected from the group of hypermobile EDS (hEDS) and classical EDS (cEDS).
3. The method of claim 1 wherein the Ehlers-Danlos Syndrome is hypermobile EDS
(hEDS).
(hEDS).
4. The method of claim 1 wherein the symptoms of Ehlers-Danlos Syndrome is one or more symptoms selected from the group consisting of pain, fatigue, range of motion, emesis, and deterioration in quality of life.
5. The method wherein the composition comprises rubeola virus in a dosage of from 0.4 TCI D50 to 400 TCI D50, more preferably 1 TCI D50 tO 10 TCI D50 and most preferably 4 TCl D50
6. The method wherein the composition comprises histamine in a dosage of from 0.001 mg to 0.1 mg, more preferably 0.01 mg to 0.05 mg and most preferably 0.008 mg.
7. The method of claim 1 wherein the histamine is a water soluble histamine salt.
8. The method of claim 1 wherein the histamine is histamine phosphate.
9. The method wherein the composition comprises collagen in a dosage of from 0.0001 mg to 0.1 mg, more preferably 0.001 mg to 0.01 mg and most preferably 0.002 mg.
10. The method of claim 1 wherein the composition further comprises lmmunoglobulin.
11. The method of claim 10 wherein the composition comprises lmmunoglobulin in a dosage of from 0.0001 mg to 0.3 mg, more preferably 0.001 mg to 0.03 mg and most preferably 0.003 mg.
12. The method of claim 10 in which the immunoglobulin is human immunoglobulin.
13. The method of claim 10 in which the immunoglobulin is lgG.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608687P | 2017-12-21 | 2017-12-21 | |
US62/608,687 | 2017-12-21 | ||
PCT/US2018/067271 WO2019126737A1 (en) | 2017-12-21 | 2018-12-21 | Compositions and methods of treatment of ehlers-danlos syndromes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3086642A1 true CA3086642A1 (en) | 2019-06-27 |
Family
ID=66993853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3086642A Pending CA3086642A1 (en) | 2017-12-21 | 2018-12-21 | Compositions and methods of treatment of ehlers-danlos syndromes |
Country Status (6)
Country | Link |
---|---|
US (1) | US11564958B2 (en) |
EP (1) | EP3727436B1 (en) |
JP (1) | JP7381086B2 (en) |
AU (1) | AU2018389242A1 (en) |
CA (1) | CA3086642A1 (en) |
WO (1) | WO2019126737A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114874316B (en) * | 2022-06-24 | 2023-06-23 | 重庆大学 | Water-soluble collagen and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4705685A (en) | 1982-05-17 | 1987-11-10 | Mcmichael John | Methods and materials for treatment of disease states involving immunological factors |
US4704273A (en) | 1982-05-17 | 1987-11-03 | Mcmichael John | Methods and materials for treatment of rheumatoid arthritis |
US4521405A (en) | 1982-05-17 | 1985-06-04 | John McMichael | Methods and materials for treatment of disease states involving immunological factors |
US6156780A (en) | 1996-10-17 | 2000-12-05 | Milkhaus Laboratory, Inc. | Treatment of fecal incontinence |
US5877198A (en) | 1996-10-17 | 1999-03-02 | Milkhaus Laboratory, Inc. | Treatment of urinary incontinence |
US20050261250A1 (en) | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
KR20070108320A (en) * | 2006-03-20 | 2007-11-09 | 전숙영 | A pharmaceutical composition for the treatment of allergic diseases and autoimmune diseases, use thereof, and a method for treatment of allergic diseases and autoimmune diseases |
JP5781764B2 (en) * | 2007-11-27 | 2015-09-24 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 14-3-3η antibody and its use for the diagnosis and treatment of arthritis |
JP6207157B2 (en) * | 2010-09-24 | 2017-10-04 | 株式会社 バイオエルティ | Pharmaceutical composition for treatment and prevention of Th3 march related diseases |
WO2014066672A1 (en) | 2012-10-26 | 2014-05-01 | Beech Tree Labs, Inc. | Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin |
EP3185881B1 (en) * | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
-
2018
- 2018-12-21 EP EP18891544.1A patent/EP3727436B1/en active Active
- 2018-12-21 US US16/956,469 patent/US11564958B2/en active Active
- 2018-12-21 JP JP2020554063A patent/JP7381086B2/en active Active
- 2018-12-21 CA CA3086642A patent/CA3086642A1/en active Pending
- 2018-12-21 WO PCT/US2018/067271 patent/WO2019126737A1/en unknown
- 2018-12-21 AU AU2018389242A patent/AU2018389242A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11564958B2 (en) | 2023-01-31 |
WO2019126737A1 (en) | 2019-06-27 |
JP7381086B2 (en) | 2023-11-15 |
EP3727436A1 (en) | 2020-10-28 |
EP3727436C0 (en) | 2023-11-15 |
EP3727436A4 (en) | 2021-07-21 |
US20200338147A1 (en) | 2020-10-29 |
JP2021506980A (en) | 2021-02-22 |
EP3727436B1 (en) | 2023-11-15 |
AU2018389242A1 (en) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014019268A1 (en) | Pharmaceutical composition for promoting nerve injury restoration and application thereof | |
Pasricha et al. | Treatment of skin diseases | |
KR20200024186A (en) | Antiviral agent for treating or alleviating adenovirus | |
CN108135965A (en) | For the pharmaceutical composition containing Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 of wound healing | |
Kaplan | Acceleration of wound healing by a live yeast cell derivative | |
EP3727436B1 (en) | Composition for treating ehlers danlos syndrome | |
CN103458912B (en) | Treat dermopathic method | |
JP2005501068A (en) | Amino acid compositions suitable for treatment for healing and / or repairing trauma and injury, especially for applications in the ophthalmic field | |
EA010945B1 (en) | Use of biocompatible polymers for the preparation of a composition or a medical device | |
ES2447829T3 (en) | Combination for the treatment of osteoarthritis | |
Barber | Benign lymphogranuloma of Schaumann with apparent involvement of the anterior pituitary | |
Walsham | Surgery: its theory and practice | |
Shreeve | The alternative dictionary of symptoms and cures | |
Tecuceanu et al. | The Particularities of Using Enzymatic Debridement Therapy in Deep Burns Treatment According to Functional Regions | |
RU2220720C1 (en) | Method for preventing disorders of ovarian-menstrual cycle and endocrine sterility in women of reproductive age in case of tick-borne neuroinfections | |
AU2018388621A1 (en) | Method of treatment of diabetic foot ulcers | |
Robinson et al. | ON A PROLONGED CASE OF TETANUS. | |
Masterman | A CASE OF ACUTE PERIOSTITIS FOLLOWED BY RAPID PYÆMIA AND DEATH. | |
Edwards | Cyclopaedia of the Diseases of Children, Medical and Surgical | |
Bechet et al. | NEW YORK DERMATOLOGICAL SOCIETY | |
Scheinberg | Stopping skin assailants: fungi, yeasts, and viruses | |
ARTERITIS | DEEMATOLOGICAL ASSOCIATION OF AUSTEALIA (BMA). CLINICAL MEETING | |
Thomas et al. | PHILADELPHIA DERMATOLOGICAL SOCIETY | |
Tauber | DERMATOLOGICAL CONFERENCE OF THE MISSISSIPPI VALLEY AND CENTRAL STATES DERMATOLOGICAL ASSOCIATION | |
Ginsberg et al. | CHICAGO DERMATOLOGICAL SOCIETY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20221116 |
|
EEER | Examination request |
Effective date: 20221116 |